Ati Pharmacology 2

ATI PHARMACOLOGY 2 1. Miscellaneous Central Nervous System Medications: Treatment for Urinary Retention, a muscarinic agonist, is used 2. Bethanechol for urinary retention. • Muscarinic agonists are indicated for nonobstructive urinary retention or on an investigational basis to treat gastroesophageal reflux. • Adverse effects include urinary urgency, bradycardia, increased gastric secretion, etc. 3. Chemotherapy Agents: Teaching About Leuprolide • Warn clients about possible hot flashes, decreased libido, and gynecomastia. • Teach client to increase intake calcium and vitamin D intake due to risk of decreased bone density. • Teach client to increase weight bearing exercises to increase bone mass. 4. Safe Medication Administration and Error Reduction: Unit-Dose Medication System • Nurse should use a unit-dose system to decrease errors. • When performing drug calculations or conversions, have another qualifies nurse double check your work. • Prepare medication dosages using standard measurement devices, such as syringes and measuring cups. 5. Eye and Ear Disorders: Adverse Effects of Beta-Adrenergic Blockers • Stinging discomfort in the eye after administration. • Occasional conjunctivitis, blurred vision, photophobia, and dry eyes. • Systemic effects of beta blockade on heart and lungs; client should notify provider if HR goes below 58 bpm. 6. Airflow Disorders: Administration of Fluticasone and Albuterol Via Metered-Dose Inhaler • Teach client to follow manufacturer’s instructions for using the device. • Teach client to shake metered-dose inhaler before administration. • Teach client to take the beta2-agonist first and then follow with the glucocorticoids. 7. Viral Infections, HIV, and AIDSL Client Teaching About HIV Medication Regimen • Teach clients to report manifestations of infection or bleeding and avoid large crowds of people who have respiratory infections. • While on ganciclovir, teach client to report signs of fever, headache, nausea, or diarrhea. • Teach client to use barrier contraception during treatment for 3 months following treatment